Ann: Strategic Partnership with Fenix Innovation Group, page-4

Not a bad deal considering the spread of things that need to be achieved for each issue of performance rights. All still highly dependant on the current clinical trials being successful.


7.5 million Neurotech performance rights to vest into shares uponNeurotech receiving an Orphan Drug Designation in the USA for anypaediatric neurological indication

• 7.5 million Neurotech performance rights to vest into shares uponNeurotech receiving an Orphan Drug Designation in Europe for anypaediatric neurological indication

• 5 million Neurotech performance rights to vest into shares uponNeurotech receiving either a US FDA IND or an EU Competent Authorityclearance for a human clinical trial in any paediatric neurologicalindication

• 10 million Neurotech performance rights to vest into shares upon:a) Neurotech signing a licence deal with a 3rd party for any of the US,European, Japanese, Canadian or Australian markets with a view togaining registration and subsequent sales of an Neurotech therapeuticproduct, andb) the shares of Neurotech to have a trading VWAP of a minimum of 25cents over 5 consecutive days in which trades in the shares occurred onASX.

• 20 million Neurotech performance rights to vest into shares upon:
a) any Neurotech therapeutic product receiving a TGA approval(provisional or otherwise) allowing it to market and sell any product inAustralia for the treatment of any paediatric neurological disorder, and
b) the shares of Neurotech to have a trading VWAP of a minimum of 30cents over 5 consecutive days in which trades in the shares occurred onASX.